Neumora Therapeutics posts corporate presentation on neuroscience drug development pipeline
PUBT · 2d ago
Share
Listen to the news
- Neumora outlined three lead programs across cardiometabolic, neurodegenerative, neuropsychiatric disease, anchored by NMRA-215, NMRA-511, NMRA-898.
- NMRA-215 NLRP3 inhibitor in obesity/CV risk: IND submission targeted for 4Q 2026; Phase 1 start planned by year-end 2026.
- NMRA-511 V1aR antagonist for agitation in Alzheimer’s disease: multiple-ascending-dose extension data expected 4Q 2026; Phase 2 initiation planned by year-end 2026.
- NMRA-898 M4 modulator for schizophrenia: Phase 1 data expected in 2H 2026.
- Preclinical NMRA-215 data showed up to 19% weight loss as monotherapy; up to 26% when combined with semaglutide.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neumora Therapeutics Inc published the original content used to generate this news brief on July 27, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending